Communiqués Tonix Pharmaceuticals Nasdaq

Actions

TNXP

US8902608624

Cours en clôture Nasdaq Autres places de cotation 00:00:00 05/02/2024			Varia. 5j.	Varia. 1 janv.
0,3222 ^USD	-2,36%		+2,32%	-20,05%

25/06	Tonix Pharmaceuticals Holding Corp. présente les données de sa plateforme vaccinale lors d'un exposé oral au Congrès des Vaccins 2024	CI
20/06	Tonix Pharmaceuticals Holding Corp. annonce une réunion CMC pré-NDA positive avec la FDA pour Tonmya dans le traitement de la fibromyalgie	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024	25/06	AQ
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia	20/06	AQ
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society	19/06	AQ
Tonix Pharmaceuticals Presented Poster of Tonmya for the Management of Fibromyalgia at the Annual European Congress of Rheumatology 2024	18/06	AQ
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)	18/06	AQ
Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024	17/06	AQ
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering	13/06	AQ
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	12/06	AQ
Tonix Pharmaceuticals Announces Proposed Public Offering	11/06	AQ
Tonix Pharmaceuticals Nears Market Entry with Tonmya for Fibromyalgia Management	11/06	AQ
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	10/06	PU
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split	06/06	AQ
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology 2024	06/06	AQ
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024	06/06	AQ
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024	05/06	AQ
Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting	03/06	AQ
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 at the American Transplant Congress 2024	30/05	AQ
Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting	30/05	AQ
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024	29/05	AQ
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention	28/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Tonix Pharmaceuticals Nasdaq

Actions

TNXP

US8902608624

Communiqués

Filtres